Alnylam Pharmaceuticals (ALNY) Prepaid Assets (2009 - 2026)
Alnylam Pharmaceuticals' (ALNY) quarterly Prepaid Assets came in at $302.2 million in Q2 2026, up 105.12% YoY from $147.3 million in Q2 2025, and up 24.81% on a QoQ basis from $242.1 million in Q1 2026.
Alnylam Pharmaceuticals (ALNY) Prepaid Assets (2009 - 2026) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has 18 years of Prepaid Assets data on file, last reported at $302.2 million in Q2 2026.
- Quarterly Prepaid Assets rose 105.12% year-over-year to $302.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $302.2 million (up 105.12% YoY) and the FY2025 annual result came in at $281.9 million, up 141.01% from the prior year.
- Prepaid Assets advanced to $302.2 million in Q2 2026, from $242.1 million in the prior quarter.
- In the past five years, Prepaid Assets ranged from a high of $302.2 million in Q2 2026 to a low of $115.1 million in Q1 2022.
- A 5-year average of $165.8 million and a median of $146.4 million in 2023 frame the typical range for Prepaid Assets.
- The widest YoY moves for Prepaid Assets: up 141.01% in 2025, down 24.53% in 2025.
- Tracing ALNY's Prepaid Assets over 5 years: stood at $132.9 million in 2022, then fell by 4.92% to $126.4 million in 2023, then decreased by 7.45% to $117.0 million in 2024, then surged by 141.01% to $281.9 million in 2025, then increased by 7.2% to $302.2 million in 2026.
- The last three Prepaid Assets figures came in at $302.2 million (Q2 2026), $242.1 million (Q1 2026), and $281.9 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 302.18 Mn |
| Mar 31, 2026 | 242.10 Mn |
| Dec 31, 2025 | 281.89 Mn |
| Sep 30, 2025 | 188.04 Mn |
| Jun 30, 2025 | 147.31 Mn |
| Mar 31, 2025 | 152.42 Mn |
| Dec 31, 2024 | 116.96 Mn |
| Sep 30, 2024 | 145.35 Mn |
| Jun 30, 2024 | 154.75 Mn |
| Mar 31, 2024 | 201.96 Mn |
| Dec 31, 2023 | 126.38 Mn |
| Sep 30, 2023 | 157.96 Mn |
| Jun 30, 2023 | 145.45 Mn |
| Mar 31, 2023 | 119.03 Mn |
| Dec 31, 2022 | 132.92 Mn |
| Sep 30, 2022 | 125.52 Mn |
| Jun 30, 2022 | 129.78 Mn |
| Mar 31, 2022 | 115.07 Mn |
| Dec 31, 2021 | 88.08 Mn |
| Sep 30, 2021 | 108.53 Mn |